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Age>60 years (p<0.001), male (p<0.001), diabetes (68%) and hypertension
(59%) were associated with SA. Most patients with SA were sleepy (Epworth
>10).
Risk factors for central SA were age>60 years, male, sever heart failure:
III-IV NYHA; diastolic dysfunction whereas risk factors for obstructive SA
were age ≥60 years (p≤0.01), male (p≤0.001), BMI ≥30 Kg/m² (p≤0.001),
Epworth score >10 (p≤0.02) and diastolic dysfunction (p≤0.05).
Multivarious analysis showed only High body mass index is associated
with obstructive SA and NYHA III-IV and low left ejection fraction were in
central SA.
Conclusions: In our HF population, SA was prevalent, frequently asymp-
tomatic and without characteristic risk factors. Unlike previously reported,
central SA was the predominant type. These results suggest that SA is under
diagnosed in HF and there is a possible correlation between them, independent
of confounding factors. Recent advances in HF therapy might influence prev-
alence and type of SA in this population.
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Background: To study short- and long-term effects of nocturnal oxygen
therapy (NOT) on sleep apnea (SA) in chronic heart failure (CHF).
Methods: In 51 consecutive stable CHF patients, NYHA II/III, left ventric-
ular ejection fraction (LVEF) ≤45%, baseline nocturnal ventilation polygraphy
identified 33 SA patients (apnea-hypopnea index (AHI) ≥15 events/h) who
were randomized to receive NOT 3 L/min (n=19) or no NOT (n=14). NOT
was applied for 6 months with a home concentrator, the first night with polyg-
raphy. Sixteen patients with NOT and 14 without NOT had polygraphy after
6 months.
Results: In patients without NOT, there was no significant difference
between baseline and the sixth month. In NOT patients, a marked AHI reduc-
tion was observed between baseline versus the first night and the sixth month,
respectively, 36.8±2.6 versus 20.8±3.0 and 18.3±2.4 events/h (p<0.0001) and
related to a central AHI decrease, respectively, 23.3±2.8 versus 8.3±1.6 and
6.1±1.4 events/h (p<0.0001). The oxygen desaturation index (ODI) evolved
similarly: 33.0±5.2 versus 7.5±0.5 and 9.3±2.6 events/h (p<0.0001). NOT had
no effects on obstructive and mixed AHI. In NOT patients versus those
without, respectively, AHI decreased by 49.0±6.0% versus increased by
2.0±14.0% (p<0.0001), ODI decreased by 59.0±9.4% versus 6.4±14.7%
(p=0.004), SaO2<90% time decreased by 61.4±9.9% versus increased by
60.0±68.4% (p=0.1) and LVEF increased by 14.5±10.2% versus 5.6±16.1%
(p=0.6). 
Conclusions: In stable CHF patients, NOT significantly reduced central
AHI and ODI, with acute effects being sustained over time and impacting nei-
ther obstructive and mixed AHI nor daytime LVEF.
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Background: After acute decompensated heart failure (ADHF), most
patients are often early discharged before treatment optimization. Following
months are important to optimize the treatment. We analyzed treatments at
discharge and at 3 months after discharge and the impact on outcome in
patients with heart failure and reduced left ventricular ejection fraction (HF-
REF).
Methods: French Society of Cardiology conducted a one-day national
survey in a randomized sample of 170 hospitals. All hospitalized patients with
a confirmed diagnosis of ADHF were included. Datas were recorded during
both hospitalizations and one-year follow up.
Results: Treatment informations at discharge as well as at 3 months were
obtained in 519 patients (age 72±14y, 34% females). At discharge, loop
diuretics were prescribed in 89% cases with daily dose of 87±146 mg, ACE-I
or ARB in 80% cases with daily dose reaching 36±31% of target dose, beta
blocker (BB) in 70% with daily dose of 27±51% of target dose, aldosterone
antagonists (AA) in 23% and digoxin in 9%. At 3 months, there was only few
changes in mean rates of prescriptions as compared to discharge (Table).
Clinical characteristics significantly associated with the lack of prescription at
3 months were creatininemia >15 mg/l for ACE-I/ARB, BB and AA, LVEF
>30% for BB and AA, and also COPD for BB.
All-cause-mortality at 12 months was 19% with marked differences
according to prescription or not of ACE-I/ARB at 3 months (15 vs 29%,
p=0.002) as well as BB (15 vs 27%, p=0.008). After adjustment on clinical
characteristics (age, blood pressure, creatininemia, LVEF, natriuretic peptides,
COPD, diabetes), lack of treatment at 3 months was an independant predictor
of mortality especially ACE-I or ARB (HR 2.50 [95%CI 1.33-4.73], p 0.005).
Conclusion: Individual treatments are poorly optimized after discharge.
Such inertia leads to poor outcome, that suggests a room to improve HF man-
agement in the practice, especially in the 3 months after discharge.
Table : Treatment changes
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Objectives: We evaluated our 10-years experience in cardiac transplanta-
tion, taking into account the evolution of recipients and donors profiles.
Methods: Between January 2000 and December 2010, 664 patients under-
went isolated cardiac transplantation. Patients transplanted between 2000 and
2004 (Group I, n=243) have been compared to patients transplanted between
2005 and 2010 (Group II, n=421).
Results: The following characteristics were significantly different between
the two groups: among the recipients, age, 45 years (group I) vs. 48 years
(group II) p=0.01; high-emergency waiting list, 1% (group I) vs. 40% (group
II), p<0.01; days on waiting list, 162 (group I) vs. 119 (group II), p=0.01; dia-
betes, 10% (group I) vs. 16% (group II), p=0.02; preoperative mechanical cir-
culatory support with VAD, 20% (group I) vs. 8% (group II), p<0.01;
preoperative ECMO, 0% (group I) vs. 16% (group II), p<0.01 ; preoperative
Treatment’s 
changes 
after 
discharges
Stared Stopped Increased 
dose
Decreased 
dose
Median 
dose at 
discharge 
[IQR]
Median 
dose at 
3 months 
[IQR]
Loop 
diuretics
7% 6% 25% 29% 40 mg/day
[40-100]
40 mg/day
[20-80]
ACE-I or 
ARB
6% 10% 21% 35% 25 % of 
target dose
[25-50]
25 % of 
target dose
[0-50]
Betablockers 8% 9% 20% 31% 25 % of 
target dose
[12.5-50]
12.5 % of 
target dose
[0-50]
Aldosterone 
inhibitors
20% 6%
